A survey of prevention, testing and treatment policies and practices
Report: A survey conducted among the 27 high MDR-TB burden countries.
March – July 2015
Stop TB Partnership in collaboration with Medecins Sans Frontieres (MSF).
Accessed November 2017.
Исследование этого года основано на предыдущем отчете. В нем отслеживается утверждение последних стратегий, руководств и методов в пяти сферах: диагностика и иссл...едование лекарственной устойчивости, режимы лечения лекарственно-чувствительного туберкулеза и туберкулеза с МЛУ, модели лечения и нормативная база.
more
MSF provides treatment for HIV and tuberculosis (TB) in more than 20 countries around the world. The report Burden sharing or burden shifting? How the HIV/TB response is being derailed examines the situation in nine countries where MSF runs programmes: Central African Republic, Democratic Republic ...of Congo, Eswatini, Guinea, Kenya, Malawi, Mozambique, Myanmar and Zimbabwe. With a focus on the financial resources available, this report highlights the current risks and gaps in HIV and TB service delivery in these countries.
Given the findings of gaps in diagnosis, prevention and care services and dwindling resources, MSF calls for a robust assessment of the needs and the resource capacity of each affected country, and calls on international donors to ensure that the financial burden is shared, rather than shifted onto those countries worst affected by the diseases.
more
TB policies in 29 Countries
A survey of prevention, testing and treatment policies and practices
TB policies in 24 Countries
A survey of prevention, testing and treatment policies and practices
Лечение туберкулеза в 24 странах
Исследование диагностической и клинической практики
This Tuberculosis guide has been developed jointly by Médecins Sans Frontières and Partners In Health. It aims at providing useful information to the clinicians and health staff for the comprehensive management of tuberculosis. Forms of susceptible and resistant tuberculosis, tuberculosis in child...ren, and HIV co-infection are all fully addressed.
more
2006-2008 programme report
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s...tandardised questionnaires and the Global TB Drug Facility website.
more
A community-based approach.
These guidelines focus on manmade rather than natural disasters, but our experiences in India, El Salvador and Pakistan (earthquake interventions), and following the 2004 tsunami, cyclone Nargis in 2008 and the Haiti earthquake in 2010, showed that the principles describ...ed also work well in contexts of natural disasters.
more
Для создания этого отчета MSF исследовала программы и практику лечения лекарственно-чувствительного и лекарственно-устойчивого туберкулеза в восьмистранах с высо...ким бременем туберкулеза, обладающих различным набором эпидемиологических, экономических, географических и демографических характеристик (Бразилия, Зимбабве, Индия, Кения, Мьянма, Российская Федерация, Узбекистан, ЮАР). Мы исследовали ключевые показатели диагностики, лечения и доступности основных препаратов, поставок лекарственныхсредств и финансирования .
more
В настоящем отчете (это уже четвертое его издание) анализируются препятствия и факторы, затрудняющие доступ к препаратам для лечения лекарственно-устойчивого туб...ркулеза, в том числе новым и применяющимся по новым показаниям.
more
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.
more
MSF International AIDS Working Group
В борьбе с туберкулезом достигнуты значительные прорывы, среди которых ускоренные и более точные методы диагностики и первые новые лекарственные средства за 50 л...т, однако сохраняется губительное отставание во внедрении этих нововведений в практику и обеспечения доступа к ним для уязвимых и социально ущемленных групп населения, в том числе заключенных, людей, живущих с ВИЧ, внутренних и внешних мигранты и наркопотребителей
more
3rd Edition – July 2017
www.msfaccess.org
Лечить пациента, а не болезнь: ориентированный на человека подход
7й симпозиум по вопросам лечения туберкулеза - презентация
This guide includes information relevant for tuberculosis (TB) program and laboratory managers, as well as Ministry of Health officials across disease programs interested in establishing integrated solutions for specimen referral. Though TB-focused in name, it offers integration-oriented assessment,... design, and monitoring guidance related to improving coordination and efficiency, and is relevant for other programs as well. Country case studies include viral load and early infant diagnosis (EID) in Uganda and EID in Ethiopia.
more